SUPN: Supernus Pharmaceuticals, Inc. Company Profile & Statistics

Supernus Pharmaceuticals, Inc. Profile

About

Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.

Info & Links

CEO

JACK A. KHATTAR

Headquarters

9715 Key West Avenue
ROCKVILLE, MD 20850, UNITED STATES

Auditor

KPMGLLP

Share holders

Employees

674

Supernus Pharmaceuticals, Inc. Statistics

Valuation Measures

Market Capitalization²

3.13B

Enterprise Value

2.99B

Enterprise Value/EBITDA(ttm)

20.75

Price to Earnings Ratio(ttm)

21.04

Price to Sales(ttm)

4.65

Price to Book(mrq)

2.91

Price to Cash(ytd)

13.22

Profitability

Gross Margin(ttm)

88.58%

Operating Margin(ttm)

22.12%

Profit Margin(ttm)

9.10%

Return on Equity(ttm)

14.22%

Return on Invested Capital(ttm)

6.27%

Return on Assets(ttm)

10.82%

Income Statement

Revenue(ttm)

665.13M

Revenue Per Share(ttm)

11.86

Gross Profit(ttm)

588.85M

EBITDA(ttm)³

144.01M

Net Income Available to Common(ttm)

64.50M

Diluted EPS(ttm)

1.15

Share Statistics

Beta (5Y Monthly)

0.75

52-Week Change

62.29%

S&P 500 52-Week Change

19.74%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

56.07M

Dividend Yield

0.00%

Float⁴

51.14M

% Held by Insiders

8.80%

% Held by Institutions

Balance Sheet

Total Cash(mrq)

522.60M

Total Cash Per Share(mrq)

9.32

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

2.58%

Quick Ratio(mrq)

2.43%

Book Value Per Share(mrq)

18.96

Cash Flow

Operating Cash Flow Per Share(ytd)

1.57

Free Cash Flow(ytd)

88.35M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

SUPN

Supernus Pharmaceuticals, Inc.